Editorial I: Postoperative NSAIDs and COX-2 inhibitors: Cardiovascular risks and benefits

British Journal of Anaesthesia

Volumn 95, Issue 3, 2005, Pages 281-284

  Jones, S F ^a   Power, Ian ^b  

^a WAIKATO HOSPITAL   (New Zealand)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETORICOXIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; KETOROLAC; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARECOXIB; PLACEBO; PROSTACYCLIN; ROFECOXIB; THROMBOXANE; VALDECOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADENOMATOUS POLYP; ALZHEIMER DISEASE; ANALGESIA; ANGIOGENESIS; ARTERY THROMBOSIS; ARTHRALGIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BINDING; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; EDITORIAL; ENZYME METABOLISM; FIRST PASS EFFECT; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; LIVER METABOLISM; LOW DRUG DOSE; META ANALYSIS; NEPHROTOXICITY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REPERFUSION INJURY; RISK BENEFIT ANALYSIS; SIDE EFFECT; SODIUM RETENTION; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM; CHEMICALLY INDUCED DISORDER; RISK ASSESSMENT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; HUMANS; POSTOPERATIVE CARE; RISK ASSESSMENT;

EID: 24944442201     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aei204     Document Type: Editorial

References (24)

1. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8
2. Solomon DH, Schneeweiss S, Glynn R et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068-73
3. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: A population study of elderly adults. Ann Intern Med 2005; 142: 481-9
4. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-4
5. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102
6. Solomon SD, McMurray JJV, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80
7. Sonksen JR, Kong KL, Holder R. Magnitude and time course of impaired primary haemostasis after stopping chronic low and medium dose aspirin in healthy volunteers. Br J Anaesth 1999; 82: 360-5
8. Green K, Drvota V, Vesterqvist O. Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins 1989; 37: 311-15
9. Bolli R. The late phase of preconditioning. Circ Res 2000; 87: 972-83
10. Birnbaum Y, Ye Y, Rosanio S et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischaemia-reperfusion injury. Cardiovasc Res 2005; 65: 345-55
11. Mamdani M, Juurlink DN, Lee DS et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population based cohort study. Lancet 2004; 363: 1751-6
12. Aw T-J, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490-6
13. Zhao SZ, Reynolds MW, Lefkowith J. et al. A comparison of renal-related adverse drug reactions between rofecoxib and celebrex, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 2001; 23: 1478-91
14. Welton A, Fort JG, Puma JA et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85-95
15. Ott E, Nussmeier NA, Duke PC et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 1481-92
16. US Food and Drug Administration. BEXTRA valdecoxib tablets. Available online at: http://www.fda.gov/cder/foi/label/2004/21341lbl.pdf
17. Analysis and recommendations for Agency action regarding NSAIDs and cardiovascular risk. Available online at: http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf
18. Hippisley-Cox J, Coupland C Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: Population based nested case-control analysis. Br Med J 2005; 330: 1366-72
19. Updated advice on the safety of selective COX-2 inhibitors. Available online at: http://www.mca.gov.uk/aboutagency/regframework/csm/csmhome.htm
20. Expanded information on COX-2 inhibitors for doctors and pharmacists. Available online at: http://www.tga.gov.au/media/2005/050214_cox2.pdf
21. Medsafe media release. Stringent conditions for COX-2 inhibitors. Available online at: http://medsafe.govt.nz/hot.htm
22. Landesberg G. The pathophysiology of perioperative myocardial infarction: Facts and perspectives. J Cardiothorac Vasc Anesth 2003; 17: 90-100
23. Beattie WS, Warriner CB, Etches R et al. The addition of ketorolac to a patient-controlled analgetic morphine regime reduced postoperative myocardial ischemia in patients undergoing elective total hip or knee arthroplasty. Anesth Analg 1997; 84: 715-22
24. Kimmel SE, Berlin JA, Kinman JL et al. Parenteral ketorolac and risk of myocardial infarction. Pharmacoepidemiol Drug Saf 2002; 11: 113-19